Metsera raises $215M for studies of GLP-1 and amylin obesity drugs
Just seven months after unveiling with $290 million, obesity biotech Metsera is back with another $215 million.
The New York-based company will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
